Brookfield Asset Management Inc. Axsome Therapeutics, Inc. Transaction History

Brookfield Asset Management Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Sep 25, 2023	SELL	$58.41 - $90.35 $705,242 - $1.09 Million	-12,074 Reduced 38.21%	19,526 $1.4 Million
Q2 2023 Aug 14, 2023	SELL	$58.41 - $90.35 $705,242 - $1.09 Million	-12,074 Reduced 38.21%	19,526 $1.4 Million
Q1 2023 Sep 25, 2023	BUY	$58.39 - $75.0 $705,000 - $905,550	12,074 Added 61.84%	31,600 $1.95 Million
Q1 2023 May 15, 2023	BUY	$58.39 - $75.0 $1.22 Million - $1.56 Million	20,822 Added 193.19%	31,600 $1.95 Million
Q4 2022 Feb 14, 2023	BUY	$39.94 - $79.72 $430,473 - $859,222	10,778 New	10,778 $831,000

Q2 2022 Nov 16, 2022	BUY	$21.74 - $46.75 $1.41 Million - $3.03 Million	64,846 New	64,846 $2.48 Million
Q2 2022 Aug 15, 2022	BUY	$21.74 - $46.75 $1.41 Million - $3.03 Million	64,846 New	64,846 $2.48 Million

290

37.1M

401K

464K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.38B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.